MT027, T-MAXIMUM's B7-H3 CAR-T therapy, earns a second FDA-cleared phase 2 trial, now testing lung and breast cancer brain metastases.
|Articles|September 15, 2019
- BioPharm International-09-15-2019
- Volume 2019 eBook
- Issue 3
Regulatory and Standard Setting Organizations
Connect with pharmaceutical and healthcare regulatory authorities around the world via this directory.
Advertisement
Connect with pharmaceutical and healthcare regulatory authorities around the world via this directory.
Articles in this issue
about 7 years ago
Global Pharmacopoeia Standards: Why Harmonization is Needed (eBook)about 7 years ago
Why Pharmacopoeia Compliance Is Difficult (eBook)about 7 years ago
Why Pharmacopoeia Compliance Is Necessary (eBook)about 7 years ago
What’s New in Regulations and Complianceabout 7 years ago
Quality Culture Drives Patient Confidence in Drug Productsabout 7 years ago
Biosimilar Quality Requirementsabout 7 years ago
Is it Time to Update cGMPs?about 7 years ago
Resources, Guidelines, and Guidance DocumentsAdvertisement
Related to this article
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Genglycos, the gene therapy that earned the voucher, will fund new Ultragenyx therapies for other rare and ultra-rare diseases.
AbbVie's c-Met ADC Temab-A showed a 15.6% response rate in late-line colorectal cancer ahead of its 2 new FDA breakthrough designations.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Patients suffered pyrogenic reactions before Fresenius Kabi recalled 3 contaminated batches at its 430,000-sq-ft Melrose Park, Ill., biologics plant.
Advertisement
Advertisement